Tag Archive for: Chief Executive Officer

Lori Gould, MTRI Executive Director

Working closely with Life Science Partner, the Middle Tennessee Research Institute has recruited Lori A. Gould as its new Executive Director.

MTRI:  Not for Profit Research Institute for the Veterans Administration, Nashville TN

Middle Tennessee Research Institute (MTRI), based in Nashville, TN, is a non-profit organization dedicated to advancing research and education for the U.S. Department of Veterans Affairs.

MTRI collaborates with the Tennessee Valley Healthcare System to enhance treatment and educational opportunities for veterans, employing a model established by federal legislation in 1988.

This organization is part of a nationwide network of 83 similar non-profit research organizations.

Executive Director Requirements

MTRI partnered with Life Science Partner to recruit its new Executive Director to drive growth and expand its non-VA funding sources. The key characteristics sought included: 

  • Entrepreneurial leadership with proven skills in organizational management.
  • Financial oversight experience with budgets up to $10 million.
  • Strategic marketing with developing successful promotional campaigns.
  • Management of teams, including recruiting staffing, planning, and budgeting capabilities to enhance research and patient care within the organization.

A Personal and Professional Project

This was both a professional and personal project for Life Science Partner’s Founder, Tom Callaway, MD.  He and his team worked closely with his first cousin, Dr. Carol Callaway-Lane, DNP, ACNP-BC. Callaway-Lane was Board President of Middle Tennessee Research Institute (MTRI), and his medical school classmate, Stokes Peebles, Jr, MD. 

Peebles is on the MTRI Board and is a Professor in the Department of Medicine, Division of Allergy, Pulmonary, and Critical Care Medicine, at Vanderbilt University Medical Center. He is the Principal Investigator of The Peebles Lab, which investigates mechanisms regulating lung inflammation.

Tom Callaway commented, “It was a pleasure working with my alma mater and two very close friends to recruit Lori to lead this innovative partnership between the VA and external research funding sources to improve the healthcare of our nation’s veterans. Nashville-based MTRI is a leading not-for-profit research organization and will accelerate its rising status and funding under Lori Gould’s tested leadership and vision.”

Lori Gould Is Recruited to Lead MTRI

Lori Gould was the perfect fit. She was most recently Executive Director of the Veterans Health Research Institute of CNY Inc. (VHRI) in Syracuse, NY, and has demonstrated outstanding leadership and commitment in her roles spanning over thirty years.  Gould’s career is marked by a continuous progression in roles with increasing responsibility, particularly in managing financial and operational systems.

Her leadership qualities, combined with a strong background in finance and technology, have contributed to the growth of the organizations she has worked with, setting a high standard in nonprofit management and operational excellence. Her career trajectory is a testament to her dedication, strategic vision, and capability to adapt and thrive in dynamic environments.

Lori Gould’s Leadership Spotlight

Since September 2010, Gould has led VHRI, a multi-site non-profit corporation (NPC) serving the Syracuse VA Medical Center and the Finger Lakes Health Care System. As Executive Director, she has effectively managed the overall operations, ensuring compliance with board directives and applicable federal and state requirements.

Her leadership spans various critical functions, including financial management, human resources, and grant administration. Gould’s ability to negotiate Cooperative Research and Development Agreement (CRADA) terms and maintain a robust pool of research coordinators exemplifies her strategic foresight and operational excellence. She has represented VHRI at various significant meetings and has solidified the organization’s position within the community.

Before this role, from September 2006 to September 2010, Gould served as the Chief Financial Officer for the same institute. Her responsibilities included overseeing all accounting functions, ensuring compliance with relevant regulations, and managing VHRI’s fiscal performance. Her strategic development of annual operating budgets and oversight of clinical trial and federal grant budgets highlight her adeptness in financial governance and resource allocation.

Between September 2005 and June 2006, Gould enriched her career portfolio as a Staff Accountant at the Diocese of Syracuse.   From October 2001 to June 2002, Gould was the Manager of Technology & Analysis at Agri-Services Agency LLC, East Syracuse, NY. She designed and implemented a new technology system to meet the company’s present and future needs, showcasing her foresight in technological integration and system management.

Gould’s contributions included revamping the accounting and billing systems and implementing collection procedures that notably reduced the receivable balance, reflecting her impact on streamlining financial operations.

Gould’s Early Career Highlights

Earlier in her career, from June 1996 to November 1997, Gould served as the Purchasing Manager at Applied Theory Communications, where she established a new purchasing department and significantly reduced expenses through strategic vendor agreements.

Her Financial/Budget Analyst role at Chesterton Company from June 1993 to November 1995 further highlights her expertise in financial analysis and budget management.

The early years of her career were spent as a Fiscal Manager at Broome BOCES – RIC in Binghamton, NY, from July 1986 to January 1993

Gould began her professional journey after graduating with a B.S. in Business Administration/Finance from the Rochester Institute of Technology in 1986.

Life Science Partner – Recruiting Transformational Leaders Like Gould

Since 2002, Life Science Partner has combined scientific knowledge with business discipline to identify and recruit the brightest talent, provide strategic advice, and connect companies with the best candidates to make their enterprises more successful.

Our targeted, high-quality executive search services meet the specific needs of medical device, biotechnology, pharmaceutical, and healthcare organizations.

How LSP Recruits Differently – Through Partnership

Life Science Partner has designed a unique and thorough approach to bringing our clients the transformational leaders needed to take their businesses to the next level.

Life Science Partner will work with your organizational needs, including the corporate culture and factors for success in the role, in order to:

  • Create a job description that captures the opportunity to attract the best and most qualified talent.
  • Strategically research, identify, and contact prospective candidates and sources.
  • Assess our best prospective candidates via telephone, Zoom, and face-to-face interviews.
  • Update you with continuous feedback on our progress in weekly meetings, written reports, and telephone calls.
  • Provide you with candidate assessment letters that convey our recommendations and reservations.
  • Conduct in-depth references on the leading candidates with a written report.
  • Assist you in negotiating an acceptable offer, with a fiduciary responsibility to our client.
  • Partner with you to ensure a successful transition into the new role, including a one-year search-again guarantee of success.

Happy Client and Its New Leader

With the recruitment of Lori Gould to lead the Nashville-based Middle Tennessee Veterans Research Institute, Life Science Partner again has demonstrated its proven formula can deliver results and provide organizations with transformative leaders. 

Congratulations to our client, Dr. Carol Callaway-Lane, DNP, ACNP-BC, Board President, and her new Executive Director, Lori Gould.

Life Science Partner has recruited Tom Afzal to become Chief Executive Officer and Board Member of Novum Medical.

Novum Medical is a private, medical device and orthopedics company developing advanced orthobiomaterials that are structurally sound and compatible to the body. Having shown success with their current applications in extremities, the company is entering the spine industry with their first cervical implant device (currently in FDA IDE clinical trials). The technology has already shown promising and superior results when compared to other implants such as titanium or PEEK plastic.

Tom Afzal

Afzal is a leader in the spine, orthopedic and cardiovascular industries. He will lead Novum in transforming the spine surgery and orthopedic markets, while continuing the growth of the company. As a co-Founder and former Chief Executive Officer of Spinal Kinetics, Afzal brought his company to profitability and led the commercial strategy for their artificial discs. He also gained extensive experience building international businesses across Europe, raising sales to over 60,000 implants in over 20 countries.

Prior to Spinal Kinetics, Afzal was the Chief Executive Officer of Cardiovention. He raised $45 M from venture capital firms, established U.S., German, and Swiss sales organizations, filed his own patents, and helped create a team to develop minimally invasive products for cardiovascular surgery.

Afzal spent the early 90s working overseas in Germany for Life System Medizintechnik and Krauth Medical, achieving annual revenue growth and leading Life System through its acquisition by Krauth Medical. He graduated from San Diego State University majoring in Business Administration and minoring in Finance.

Afzal will play a critical role in raising funds for Novum Medical with his financing background and connections in the spine, cardiovascular and sports medicine industries. As the company completes its FDA IDE clinical trials for their Vitrium cervical interbody spinal fusion device, Afzal will leverage his strengths in commercial and operational leadership to advance the company to its next level of growth.

Novum Medical is a private, medical device and orthopedics company developing advanced orthobiomaterials that are structurally sound and compatible to the body. Having shown success with their current applications in extremities, the company is entering the spine industry with their first cervical implant device (currently in FDA IDE clinical trials). The technology has already shown promising and superior results when compared to other implants such as titanium or PEEK plastic.

Afzal is a leader in the spine, orthopedic and cardiovascular industries. He will lead Novum in transforming the spine surgery and orthopedic markets, while continuing the growth of the company. As a co-Founder and former Chief Executive Officer of Spinal Kinetics, Afzal brought his company to profitability and led the commercial strategy for their artificial discs. He also gained extensive experience building international businesses across Europe, raising sales to over 60,000 implants in over 20 countries.

Prior to Spinal Kinetics, Afzal was the Chief Executive Officer of Cardiovention. He raised $45 M from venture capital firms, established U.S., German, and Swiss sales organizations, filed his own patents, and helped create a team to develop minimally invasive products for cardiovascular surgery.

Afzal spent the early 90s working overseas in Germany for Life System Medizintechnik and Krauth Medical, achieving annual revenue growth and leading Life System through its acquisition by Krauth Medical. He graduated from San Diego State University majoring in Business Administration and minoring in Finance.

Afzal will play a critical role in raising funds for Novum Medical with his financing background and connections in the spine, cardiovascular and sports medicine industries. As the company completes its FDA IDE clinical trials for their Vitrium cervical interbody spinal fusion device, Afzal will leverage his strengths in commercial and operational leadership to advance the company to its next level of growth.

About Life Science Partner Executive Search

Life Science Partner is a specialized executive search firm that recruits transformational leaders for healthcare and life sciences companies. Our high-touch, partner-led process ensures an exceptional level of service, while our backgrounds in medicine, science, and industry enable us to efficiently deliver the brightest candidates in the medical device, biopharmaceuticals, diagnostics, and healthcare technology fields.

Life Science Partner is pleased to announce the recruitment of Peter Wehrly as Chief Executive Officer with Vivex Biologics.

Vivex Biologics is a leading regenerative medicine company that markets tissue technology products and cellular therapies focused on orthopaedic applications with an emphasis on spine related therapies. They have a diverse portfolio of current products including cellular bone matrices, amniotic tissue, general orthopaedics, and sports medicine products to meet the therapeutic demand in the areas of spine, dental, sport medicine, and wound care. 

Peter Wehrly

Vivex is preparing for its next stage of growth with the launch of its VIA Disc product, a paradigm-changing treatment for Degenerative Disc Disease (DDD). As the company moves into the biologics space, it sought a seasoned Chief Executive to lead the company through its next stage of growth.

Wehrly is a leader in the spine and orthobiologics industries and will help lead Vivex Biologics’ expansion of their sales force and guide the company through continued growth. He is a strategic leader with a broad background in growth and operational efficiencies within public and private companies in the medical device industry. Prior to joining Vivex, Wehrly served as Chief Executive Officer with Synaptive Medical, where he led a global team launching the 2nd generation disruptive surgical robotic technology portfolio across North America, Western Europe, and Asia.

He was also Chief Executive at PQ Bypass, where he led a cross-functional team in gaining CE Mark for their Detour System, a technology designed to advance the treatment of long-segment peripheral artery disease, and approval to embark on their PMA trial in the US and Europe.

Previously, Wehrly served as Group President for Covidien where he turned around the Respiratory and Monitoring Solutions business and was later responsible for the Vascular Therapies business. Wehrly is a seasoned executive in the spine industry having led several divisions of Medtronic including Spinal and Biologics for 8 years. He played an integral role in their global market leadership positions and saw them grow from $500M to over $2.8B in compound annual growth rate.

Wehrly will play a pivotal role in helping Vivex Biologics during its next stage of growth and development as they launch a new product in the biologics space, leveraging his expertise in the spine industry and his commercial and operational strengths to ensure continued growth and preparation for a future financing event.

About Life Science Partner

Life Science Partner is a specialized executive search firm that recruits transformational leaders for healthcare and life sciences companies. Our high-touch, partner-led process ensures an exceptional level of service, while our backgrounds as physicians and industry executives enable us to efficiently deliver the brightest candidates in the medical device, biopharmaceuticals, diagnostics, and healthcare technology fields.

Life Science Partner is pleased to announce the recruitment of Mark Alvarez to Irrimax, where he will serve as Chief Executive Officer.

Irrimax is an Atlanta-based medical technology company that is redefining wound irrigation with Irrisept, the only FDA-cleared medical device for irrigation containing the proven antiseptic chlorhexidine gluconate (CHG).

Mark Alvarez

Alvarez was most recently Chairman, President & CEO of BC Technical, a healthcare services company focused on diagnostic imaging solutions for hospitals & clinics across the US. BCT was acquired in 2017 by Alpha Source, a portfolio company of Baird Capital. Prior to his BC Technical role, Mark was Chairman-Elect & COO of Microtek Medical (Nasdaq:MTMD), a global manufacturer of custom infection control products acquired by Ecolab.

“Mark is a high-energy executive who has demonstrated the ability to fund, grow, and sell small to mid-sized healthcare companies but also has held P&L responsibility in a large global medtech organization,” commented Tom Callaway, MD, MBA, President of Life Science Partner. “His strategic experience in the infection control space will be indispensable to Irrimax during this important inflection point in the company’s growth.”

Alvarez earned a MBA from Illinois State University, a Bachelor’s degree in Biology from the University of Louisville, and has completed multiple executive programs at the GE Leadership Institute. He is a former professional tennis player and lives in Atlanta.

About Life Science Partner Executive Search

Life Science Partner is a specialized executive search firm that recruits transformational leaders for healthcare and life sciences companies. Our high-touch, partner-led process ensures an exceptional level of service, while our backgrounds as physicians and industry executives enable us to efficiently deliver the brightest candidates in the medical device, biopharmaceuticals, diagnostics, and healthcare technology fields.

Life Science Partner is pleased to announce the recruitment of Pamela Goldberg to lead the Medical Device Innovation Consortium as President and Chief Executive Officer.

Prior to starting her own consulting firm in 2017, Ms. Goldberg served as the CEO of the Massachusetts Technology Collaboration, a public economic development engine designed to foster technological advancements, where she helped launch Massachusetts to national leadership for adoption and interoperability of electronic medical records and collaborated to build the health information exchange connection to the EHR.

She will succeed Bill Murray as CEO, whom Life Science Partner recruited at the organization’s inception, and is well-suited to lead MDIC into its next phase of growth and impact, building on the foundational successes of Mr. Murray and his team.

Pamela Goldberg

“Pamela’s solid entrepreneurial experience synergizing objectives for multiple government and for-profit institutions, combined with her successful leadership experience in digital health advancements, leveraging big data, and advancing healthcare technological innovation, make her uniquely suited to lead this pioneering organization,” said Tom Callaway, MD, Founder and President of Life Science Partner. “We are confident MDIC and the many stakeholders it serves will benefit greatly from her thoughtful leadership in the months and years to come.”

Ms. Goldberg has demonstrated consistent success in working across the boundaries of government, in both non-profit and private industry and with regulatory bodies to drive consensus. Previously, Ms. Goldberg served as director of The Center for Entrepreneurial Leadership at Tufts University, a program she launched to drive innovation for the university. Ms. Goldberg received her BA from Tufts University and her MBA from Stanford University.

The MDIC, through its public-private partnership between government and regulatory agencies, non-profits, and the medical device industry, aims to advance regulatory science and bring innovative technologies to patients. MDIC coordinates the development of methods, tools, and resources used in managing the medical device life cycle to improve patient access to cutting-edge medical technology.

About the Medical Device Innovation Consortium

Founded in 2012, the Medical Device Innovation Consortium (MDIC) is the first public-private partnership created with the sole objective of advancing medical device regulatory science throughout the total product life cycle. MDIC’s mission is to promote public health through science and technology and to enhance trust and confidence among stakeholders.

MDIC works in the pre-competitive space to facilitate development of methods, tools, and approaches that enhance understanding and improve evaluation of product safety, quality, and effectiveness. Its initiatives improve product safety and patient access to cutting-edge medical technology while reducing cost and time to market.

About Life Science Partner Executive Search

Life Science Partner is a specialized executive search firm that recruits transformational leaders for healthcare and life sciences companies. Our high-touch, partner-led process ensures an exceptional level of service, while our backgrounds as physicians and industry executives enable us to efficiently deliver the brightest candidates in the medical device, biopharmaceuticals, diagnostics, and healthcare technology fields.

More information is available here.

Former President and Chief Executive Officer of Vascular Pathways

Life Science Partner has recruited Bill Bold, former CEO of Vascular Pathways and senior medical device leader, to become Chief Executive Officer for Vestagen, an innovator in the development of Active Barrier fabrics and protection technology to protect the healthcare worker.

Prior to joining Vestagen, Bold turned around Vascular Pathways with product innovation and commercialization and sold the company to CR Bard for its best-in-class portfolio of peripheral vascular access technologies. “Bold is an articulate, strategic and a strong leader who recruits world-class teams to early-stage companies,” stated Tom Callaway, MD, Founder and President of Life Science Partner and Venture Partner at HealthQuest Capital, an investor in the company.

“With a track record for delivering a strong return on investment in fundraising with venture capital and private equity, Bold has the experience to lead Vestagen’s growth and profitability within the healthcare industry,” noted Callaway.

Prior to joining Vascular Pathways, Bold held executive leadership roles for both early stage and corporate divisions of medical device companies such as Access Scientific, Venetec, Medibuy and CR Bard.

Bold earned a Bachelor of Science Degree in Marketing from West Chester University.

Learn More About Life Science Partner

Click button below to find out more about how we recruit Chief Executives:

Former President and CEO of ReShape Medical

Life Science Partner recruited Bill Murray, to become the President and Chief Executive Officer for the Medical Device Innovation Consortium (MDIC), the first-ever public-private partnership created to advance medical device regulatory science and technology environment.

Murray has over 25 years of senior leadership experience spanning the range of privately financed start-up to billion dollar plus global businesses. Murray’s small company experience spans 5 years as CEO and executive consultant, including 3 years as CEO of ReShape Medical. His large company experience includes leadership as the Molecular Biology Division President of Applied Biosystems, and at Medtronic where he spent nearly 20 years in various senior leadership positions, including President of the Pacemaker Business.

Murray has also served as interim President and CEO of MTS Systems (MTSC) a public $500M industrial technology company. He currently serves on the Boards of MDIC, ILT, Sonex Health and Meso-FLow and previously served on the Boards of MTS Systems, LifeSync Holdings, and ReShape Medical.

Murray earned his Bachelor of Science Degree in Electrical Engineering from the University of Florida.

Life Science Partner recruits former Senior Vice President, Business and Commercial Development from ACADIA Pharmaceuticals

Life Science Partner announces the recruitment of Brian Lundstrom, an experienced biopharmaceutical business development executive, to Windy Hill Medical to become Chief Executive Officer for the company.

Windy Hill Medical is a California-based medical device and pharmaceutical company focused on the development of products to reduce the risk of developing breast cancer in patients deemed to be at high risk.

In Lundstrom’s previous role at ACADIA, a San Diego-based biopharmaceutical company developing small molecule therapeutics for the central nervous system, he was responsible for developing partnerships, particularly with Asian and European pharmaceutical companies, for the company’s four clinical-stage and preclinical programs.

Prior to joining ACADIA, Lundstrom served as Vice President of Business Development and Humanized Polyclonal Antibody Program Manager for Genzyme Corporation in the areas of Oncology, Hematology Transplantation and Immunology. 

In his new role as Chief Executive Officer, he will lead the Company through an additional round of financing, the development and expansion of the clinical trial program, and commercialization of its product portfolio.

“Lundstrom is an experienced and effective global biopharmaceutical manager with a broad background in business development and partnering,” noted Tom Callaway, MD, founder and president of Life Science Partner.  “With his passion and experience, he will serve Windy Hill well in its mission to bring lasting improvements for patients with early-stage breast cancer.”

Lundstrom earned his Master of Science degree in Chemical Engineering with an immunology and molecular biology focus from the Danish Technical University in Lyngby, Denmark.  He attended the Copenhagen Business School and earned a diploma in Economics in International Management.  Lundstrom received his PhD in Biochemistry from Odense University and then attended the Monterey Institute of International Studies in Monterey, CA for an MBA program.

Learn More About Life Science Partner

Click button below to learn more about how we recruit Chief Executives:

Life Science Partner recruits former Senior Vice President, Sales and Marketing for Vermillion.

Life Science Partner announces the recruitment of Steve Lundy, a top commercial executive in early-stage diagnostics companies, to MicroPhage, an early-stage company based in Longmont, Colorado. 

Using its proprietary bacteriophage-based technology, MicroPhage is developing rapid assays for the direct identification and drug susceptibility of deadly bacterial strains such as Methicillin Resistant Staphylococcus Aureus (MRSA).

Most recently, Lundy was the Senior Vice President of Sales and Marketing for Vermillion, where he helped lead the company’s transformation from life sciences to a clinical diagnostics business model.

Lundy previously served as Vice President of Sales, Marketing and Business Development for GeneOhm Sciences.  He led the launch of the IDI-MRSA(TM) assay, the first nucleic-acid based test to be cleared by regulatory agencies to replace conventional microbiological culture by directly testing the clinical specimen. GeneOhm was acquired by BD (Becton, Dickinson and Company) in 2006.

“Lundy is a seasoned diagnostics industry leader who understands the market and the opportunity,” noted Tom Callaway, MD, President and Founder of Life Science Partner.  “He brings an unsurpassed depth of experience in infectious disease  diagnostics from GeneOhm to capitalize upon MicroPhage’s novel platform for MRSA detection.”

Lundy received his Bachelor of Science degree from the United States Air Force Academy in Colorado.

Learn More About Life Science Partner

Click button below to learn more about how we recruit Chief Executives:

Life Science Partner recruits senior biotechnology entrepreneurial and Co-Founder and Chairman of North Carolina Innovation Foundation.

Life Science Partner announces the recruitment of Max Wallace, a biotechnology CEO and innovative leader, to lead Accelerate Brain Cancer Cure, Inc.

ABC2 is a not-for-profit organization established in 2001 with a for-profit mindset and a singular focus: to hasten the discovery of a cure for brain cancer.  Founded by the Case , the ABC2 has an entrepreneurial model of identifying and funding critical research into brain cancer and catalyzing interdisciplinary collaboration works.

Wallace shares the ABC2 passion for using a not-for-profit model for pushing forward new drug development – particularly to treat diseases ignored by big pharma companies due to low prevalence and smaller markets.

Max Wallace is Chief Executive Officer of TheraLogics, an early-stage biopharmaceutical company based on technology developed by Dr. Albert Baldwin at the University of North Carolina.  He previously co-founded and served as President of Trimeris, a public biopharmaceutical company that created and brought to market the world’s first entry inhibitor, establishing a new class of drugs for HIV/AIDS and other viral diseases.  He also founded and developed several other biopharmaceutical companies, including Sphinx Pharmaceuticals Corporation (now a division of Eli Lilly & Co); SARCO (now a part of PPD/Pharmaco); and Cogent Neuroscience.

“Max is a dynamic leader who knows how to bring a team together and motivate them around a common goal,” noted Tom Callaway, MD, founder and president of Life Science Partner.  “He will bring his exceptional entrepreneurial instincts and innovative not-for-profit expertise together to provide the visionary and strategic leadership needed to fulfill ABC’s important mission.”

Wallace received his Bachelors degree Duke University and earned his law degree from the University of Florida College of Law in Gainesville, Florida.

Learn More About Life Science Partner

Click button below to learn more about how we recruit Chief Executives: